title: Acute lymphoblastic leukaemia in a Jehovah's Witness: a management dilemma.
abstract: Jehovah's witnesses represent a unique group of patients whose religious beliefs prohibit receiving transfusion of all blood products. Since most chemotherapeutic regimens used to treat acute leukemia are myelosuppressive and often resulting in potentially life threatening pancytopenia, their refusal of blood products poses a challenge to clinicians. We report a case of a Jehovah's Witness patient with acute lymphoblastic leukemia (ALL) who was successfully treated with non-myelosuppressive chemotherapy for both first and second remission and achieved complete remissions both times without transfusion of blood products.
authors.forename: Louise
authors.initials: L
authors.lastname: Zhou
authors.forename: Amr
authors.initials: A
authors.lastname: Mohsen
authors.forename: Mohammad A
authors.initials: MA
authors.lastname: Khan
authors.forename: Troy
authors.initials: T
authors.lastname: Guthrie
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D033221:Jehovah's Witnesses; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D015452:Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*
keywords: Acute lymphoblastic leukemia; Chemotherapy,; Jehovah’s witness,